🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Acoramidis (AG10)

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 3 small molecule active

    1 trial

  2. Active referral

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 3 other active

    1 trial

  3. Acyclovir

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  4. Adderall-XR

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 3 small molecule completed

    1 trial

  5. Agitated Saline SoC

    BRIGHT MINDS BIOSCIENCES INC.

    Right-To-Left Shunt

    phase 3 small molecule active

    1 trial

  6. Aldurazyme

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    phase 3 mab completed

    1 trial

  7. Anakinra

    Swedish Orphan Biovitrum AB (publ)

    Still's Disease, Juvenile Onset

    phase 3 small molecule active

    1 trial

  8. Azvudine

    Shanghai Henlius Biotech

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  9. B007

    BRIGHT MINDS BIOSCIENCES INC.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. B007

    BRIGHT MINDS BIOSCIENCES INC.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    2 trials

  11. B013+Nab-Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Triple Negative Breast Cancer (TNBC)

    phase 3 small molecule completed

    1 trial

  12. BAT5906 injection

    Bio-Thera Solutions

    Diabetic Macular Edema (DME)

    phase 3 small molecule active

    1 trial

  13. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  14. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  15. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  16. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  17. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  18. BG00012

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  19. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  20. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  21. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  22. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  23. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  24. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources